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The	clinical	significance	of	non-HLA	antibodies	on	renal	allograft	survival	is	a	matter	of	
debate,	due	to	differences	in	reported	results	and	lack	of	large-scale	studies	incorpo-
rating	analysis	of	multiple	non-HLA	antibodies	 simultaneously.	We	developed	a	mul-
tiplex	non-HLA	antibody	assay	against	14	proteins	highly	expressed	 in	 the	kidney.	 In	
this	study,	the	presence	of	pretransplant	non-HLA	antibodies	was	correlated	to	renal	
allograft	survival	in	a	nationwide	cohort	of	4770	recipients	transplanted	between	1995	
and	2006.	Autoantibodies	against	Rho	GDP-dissociation	 inhibitor	2	 (ARHGDIB)	were	
significantly	 associated	 with	 graft	 loss	 in	 recipients	 transplanted	 with	 a	 deceased-
donor	kidney	(N	=	3276)	but	not	 in	recipients	of	a	 living-donor	kidney	(N	=	1496).	At	
10	years	after	deceased-donor	transplantation,	recipients	with	anti-ARHGDIB	antibod-
ies	(94/3276	=	2.9%)	had	a	13%	lower	death-censored	covariate-adjusted	graft	survival	
compared	to	the	anti-ARHGDIB-negative	(3182/3276	=	97.1%)	population	(hazard	ratio	
1.82;	95%	confidence	interval,	1.32-2.53;	P	=	.0003).	These	antibodies	occur	indepen-
dently	from	donor-specific	anti-HLA	antibodies	(DSA)	or	other	non-HLA	antibodies	in-
vestigated.	No	significant	relations	with	graft	loss	were	found	for	the	other	13	non-HLA	
antibodies.	We	suggest	that	pretransplant	risk	assessment	can	be	improved	by	measur-
ing	anti-ARHGDIB	antibodies	in	all	patients	awaiting	deceased-donor	transplantation.
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1  | INTRODUC TION
Chronic	kidney	disease	affects	about	10%	of	the	global	population.1 
Over	2	million	people	worldwide	currently	receive	dialysis	treatment,	
or	 are	 recipients	 of	 a	 kidney	 transplant.	 Kidney	 transplantation	 is	
the	preferred	treatment	for	end-stage	renal	disease	due	to	superior	
quality	of	life	and	survival	rates.	However,	although	short-term	renal	
allograft	survival	has	improved	considerably	in	the	last	20	years,	an-
tibody-mediated	rejection	(ABMR)	remains	one	of	the	major	causes	
of	graft	loss	and	of	deterioration	of	graft	function	in	the	long-term.	
Donor-specific	anti-HLA	antibodies	(DSA)	are	well	known	to	play	an	
important	role	in	this	process.	Nonetheless,	(subclinical)	ABMR	oc-
curs	also	in	the	absence	of	DSA,	which	has	sparked	interest	 in	the	
short-	and	long-term	clinical	relevance	of	donor-reactive	antibodies	
recognizing	proteins	other	than	HLA	(ie,	non-HLA-antibodies).2
The	clinical	relevance	of	non-HLA	antibodies	on	graft	survival	is	not	
clear.3,4	Although	it	has	been	reported	that	non-HLA	antibodies	against	
Angiotensin	II	type	1	receptor	(AT1R)	are	an	independent	risk	factor	for	
long-term	graft	loss,5	others	could	not	replicate	these	findings,6,7	which	
may	be	caused	by	the	inclusion	or	exclusion	of	patients	with	pretrans-
plant	DSA.	However,	 antibody-mediated	 rejection	of	 renal	 allografts	
from	HLA-identical	 sibling	donors	and	also	 from	deceased	donors	 in	
the	absence	of	pretransplant	DSA	has	been	reported	several	times.8,9 
And	recently	it	was	reported	that	the	development	of	circulating	nat-
ural	antibodies	posttransplant	is	associated	with	poorer	graft	survival,	
worse	graft	function,	and	more	microvascular	injury.10
Non-HLA	 antibodies	 have	 been	 described	 against	 a	 variety	 of	
targets,	but	 large-scale	 studies	 incorporating	analysis	of	 these	an-
tibodies	 simultaneously	 to	assess	 their	 clinical	 relevance	 in	kidney	
transplantation	are	lacking.	In	this	retrospective	study	on	a	large	na-
tional	 cohort	of	4770	 renal	 transplant	 recipients,	we	assessed	 the	
impact	on	graft	survival	of	IgG	autoantibodies	against	14	previously	
identified	target	proteins.11
2  | MATERIAL S AND METHODS
2.1 | Study population
Between	 January	 1995	 and	 December	 2005,	 6097	 kidney	 trans-
plantations	 with	 a	 negative	 complement-dependent	 cytotoxicity	
crossmatch	were	performed	in	The	Netherlands.	Clinical	data	were	
obtained	from	the	Dutch	Organ	Transplant	Registry.	The	use	of	sera	
and	 experimental	 protocols	 was	 approved	 by	 the	 Research	 Ethics	
Committee	 for	Biobanks	and	 the	Medical	Ethics	Committee	of	 the	
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University	Medical	Center	Utrecht.	Experimental	protocols	were	per-
formed	in	accordance	with	the	Federation	of	Dutch	Medical	Scientific	
Societies	Code	of	Conduct.	The	study	was	conducted	in	accordance	
with	the	2013	Declaration	of	Helsinki	and	the	2008	Declaration	of	
Istanbul.	Of	4787/6097	(78%)	transplantations,	pretransplant	serum	
was	available.	Seventeen	transplantations	were	excluded	due	to	lack	
of	follow-up,	and	the	remaining	4770	transplantations	were	included	
in	this	analysis.	Minimal	follow-up	time	was	10	years	after	transplan-
tation.	Data	available	on	request	due	to	privacy/ethical	restrictions.
2.2 | Assessment of non‐HLA antibodies
We	 selected	 14	 non-HLA	 target	 proteins	 from	 the	 literature.11 
Antibodies	 against	 the	 glomerular	 basement	 membrane	 pro-
tein	 agrin	 have	 been	 described	 in	 the	 context	 of	 transplant	
glomerulopathy.12	 Antibodies	 against	 adipocyte	 plasma	 mem-
brane-associated	 protein	 (APMAP),	 Rho	 GDP-dissociation	 in-
hibitor	 2	 (ARHGDIB),	 Rho	 guanine	 nucleotide	 exchange	 factor	
6	 (ARHGEF6),	 Lamin	B1,	BPI	 fold-containing	 family	B	member	1	
(LPLUNC1),	protein	kinase	C	zeta	type	(PRKCZ),	and	tubulin	beta-
4B	(Tubb4B)	were	all	demonstrated	either	in	chronic	hemodialysis	
patients	 or	 patients	 awaiting	 kidney	 transplantation.	 Antibodies	
directed	 against	 targets	 expressed	 on	 the	 endothelium,	 that	 is,	
AT1R	and	endothelin	type	A	receptor	(ETAR),	were	reported	to	be	
involved	directly	or	indirectly	in	renal	disease.	Antibodies	against	
the	intracellular	proteins	vimentin	and	peroxisomal	trans-2-enoyl-
CoA	reductase	(PECR)	have	been	reported	to	be	associated	with	
allograft	 failure.13,14	 Pre-	 and	 posttransplant	 endorepellin	 anti-
body	 levels	were	 increased	 in	 patients	with	 vascular	 rejection15 
and	 phospholipase	 A2	 receptor	 (PLA2R)	 antibodies	 are	 strongly	
associated	 with	 primary	 membranous	 nephropathy.16	 We	 com-
mercially	 purchased	 all	 proteins	 with	 the	 exception	 of	 PLA2R,	
which	was	produced	in-house,	and	coupled	these	proteins	directly	
with	carboxylated	MagPlex	Microspheres	(Luminex	Corp,	Austin,	
TX)	as	recommended	by	Luminex.17	 In	addition,	we	produced	12	
of	the	14	proteins	with	a	HaloTag,	with	the	exception	of	AT1R	and	
PECR.	 The	HaloTag	 proteins	were	 coupled	 via	 a	 HaloTag	 Amine	
(O4)	Ligand	(Promega,	Madison,	WI)	to	the	carboxylated	MagPlex	
microspheres.	A	detailed	description	of	the	proteins	and	the	cou-
pling	methods	is	given	elsewhere.11
A	mix	of	31	different	microspheres	was	made	containing	15	di-
rectly	 coupled	proteins	 (transferrin	 and	14	 target	 proteins),	 13	 in-
house	produced	HaloTag-coupled	proteins	(transferrin	and	12	target	
proteins),	 an	 IgG-coupled	microsphere	as	 a	positive	 control,	 and	a	
HaloTag	amine-coupled	and	empty	microsphere	as	additional	nega-
tive	controls.	Transferrin	(directly-	or	HaloTag-coupled)	also	served	
as	a	negative	control,	since	it	is	ubiquitously	present	and	no	autoan-
tibodies	against	transferrin	have	been	reported.	Sera	(1:25	dilution)	
were	 incubated	overnight	with	 the	microsphere	mix.	Next,	R-phy-
coerythrin-conjugated	goat-anti	human	antibody	was	added.	After	
30	minutes	of	incubation,	wash	buffer	was	added	and	samples	were	
measured	on	a	Luminex	200	flow	analyzer	(Luminex	Corp).
2.3 | Histology
Three-micrometer	formalin-fixed	paraffin-embedded	sections	were	
used.	After	antigen	retrieval	 in	citrate	solution	pH	6,	primary	anti-
body	against	ARHGDIB	(Biobyt,	San	Francisco,	CA)	was	applied	in	a	
1:2000	solution	for	1	hour	at	room	temperature,	followed	by	HRP-
labeled	 polymer	 anti-rabbit	 Ig	 detection	 antibody	 (BrightVision,	
VWR,	Duiven).	Bound	antibody	was	visualized	with	Nova	Red	sub-
strate	 (Vector	 labs),	 and	 finally	 nuclei	 were	 counterstained	 with	
hematoxylin.
2.4 | Statistical analysis
Because	the	Kaplan-Meier	estimates	were	biased	due	to	unbalanced	
distribution	of	confounders,	death-censored	graft	survival	was	as-
sessed	using	the	adjusted	Kaplan-Meier	estimator	(AKME)	based	on	
inverse	probability	weighting	 (IPW).	Each	observation	 is	weighted	
by	its	inverse	probability	of	being	in	a	certain	group.18	Hazard	ratios	
(HRs)	 and	95%	 confidence	 intervals	 (95%	CIs)	were	 derived	 using	
multivariable	Cox	regression.	A	Bonferroni	correction	was	used	to	
adjust	for	multiple	comparisons	when	studying	the	effects	of	non-
HLA	antibodies	on	graft	 survival	 and	P	 <	 .002	 (.05	divided	by	25	
non-HLA	antibodies)	was	considered	as	statistically	significant	(ap-
plied	for	analyses	in	Tables	1,	S3,	and	S4).	We	adjusted	in	both	the	
AKME	and	Cox	 regression	 for	 recipient	age	 (quadratic)	and	donor	
age	 (quadratic),	 cold	 ischemia	 time	 (for	donation	after	brain	death	
or	 cardiac	 death),	 years	 on	 dialysis	 (quadratic),	 induction	 therapy	
TA B L E  1  Multivariable	analyses	of	the	effect	of	antibodies	against	ARHGDIB	on	10-year	death-censored	graft	failure
 
No. (%) of transplantations 
with anti‐ARHGDIB antibodies Hazard ratio 95% CI P‐value
Total	cohort	(N	=	4770) 134	(2.8) 1.701 1.265-2.288 .0004
Deceased	donors	(N	=	3276) 94	(2.9) 1.820 1.318-2.531 .0003
Living	donors	(N	=	1494) 40	(2.7) 1.249 0.587-2.657 .5639
Note:	In	this	multivariable	analysis	we	evaluated	the	effect	of	the	presence	of	pretransplant	ARHGDIB	on	the	10-year	death-censored	graft	failure	
and	adjusted	for	differences	in	the	following	covariates:	recipient	age	(quadratic),	donor	age	(quadratic),	donor	type	(living	or	deceased,	only	for	
the	total	cohort),	cold	ischemia	time	in	hours	for	donation	after	brain	death	(DBD)	and	donation	after	cardiac	death	(DCD),	time	on	dialysis	in	years	
(quadratic),	induction	therapy	with	Interleukin-	2	receptor–blocking	antibody	and	the	presence	of	pretransplant	donor-specific	anti-HLA	antibodies	
against	HLA-A/B/DR/DQ.	CI,	confidence	interval.	A	Bonferroni	correction	was	used	to	adjust	for	multiple	comparisons	with	P < .002 considered as 
statistically	significant.
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with	IL-2	receptor	blocker,	and	the	presence	of	pretransplant	single	
antigen	bead-defined	DSA	against	HLA-A/B/DR/DQ.	(For	more	de-
tailed	descriptions	see	Kamburova	et	al.19)	Statistical	analyses	were	
performed	with	R	version	3.4.1	and	SAS	version	9.4	(SAS	Institute,	
Cary,	NC).	Continuous	data	were	analyzed	with	the	Mann-Whitney	
U	test	and	categorical	data	with	the	chi-square	test.
3  | RESULTS
3.1 | Determination of a clinically relevant cut‐off 
for the presence of non‐HLA antibodies
We	 analyzed	 the	 4770	 pretransplant	 sera	 using	 our	multiplex	 non-
HLA	 assay,	 and	 the	 individual	 median	 fluorescence	 intensitiy	 (MFI)	
values	with	box	and	whisker	plots	are	shown	in	Figure	S1.	As	we	ob-
served	relatively	high	background	signals	for	some	sera	(Figure	S1A),	
we	decided	to	use	signal-to-background	ratios	(STBRs)	as	a	parameter	
to	determine	non-HLA	antibody	positivity.	The	correlation	between	
the	MFI	of	transferrin	(directly-	or	HaloTag-coupled)	and	the	MFIs	of	
target	microspheres	was	stronger	than	the	correlation	between	MFI	of	
other	negative	control	microspheres	and	that	of	target	microspheres	
(data	not	shown).	Therefore,	transferrin	was	selected	as	the	most	op-
timal	negative	control,	and	was	used	correspondingly	to	calculate	the	
STBRs	(Figure	S2).	To	determine	the	clinically	relevant	cut-off,	we	ana-
lyzed	the	impact	on	1-,	5-,	and	10-year	death-censored	graft	survival	
of	various	cut-offs	for	each	antibody	in	a	univariate	analysis	(Figure	1).	
For	each	non-HLA	antibody,	we	selected	the	ratio	and	absolute	MFI	
cut-off	that	resulted	in	the	highest	difference	in	graft	survival	between	
the	antibody-negative	and	antibody-positive	group.	For	ARHGDIB,	a	
ratio	of	10	in	combination	with	an	absolute	MFI	of	500	was	chosen	
as	cut-off	values	using	the	directly	coupled	microspheres,	resulting	in	
134/4770	(2.8%)	positive	patients	(Figure	1).	An	overview	of	the	se-
lected	cut-offs	for	the	other	non-HLA	antibodies	based	on	the	maxi-
mal	graft	survival	difference	is	summarized	in	Table	S1.	Depending	on	
the	type	of	non-HLA	antibody	analyzed,	percentages	of	positive	sera	
ranged	from	0.9%	to	2.8%,	and	varying	differences	were	observed	in	
1-,	5-,	and	10-year	graft	survival.
3.2 | Impact of pretransplant non‐HLA antibodies 
on long‐term graft survival
After	 Bonferroni	 correction,	 a	 significant	 difference	 in	 graft	 sur-
vival	was	observed	between	patients	with	pretransplant	antibodies	
against	ARHGDIB	compared	to	patients	without	antibodies	against	
this	target	(Table	1).	No	significant	relation	with	graft	 loss	was	ob-
served	for	the	other	non-HLA	antibodies.	A	summary	of	the	impact	
of	 the	 other	 non-HLA	 antibodies	 on	 10-year	 graft	 survival	 of	 the	
total	cohort	is	summarized	in	Table	S2.
Because	our	cohort	contained	a	 relatively	high	proportion	of	
living	 donors	 and	 we	 previously	 found	 that	 DSA	 had	 mainly	 an	
impact	 on	 deceased-donor	 transplantations	 with	 only	 a	 limited	
effect	on	living-donor	transplantations,19	we	also	analyzed	the	im-
pact	of	non-HLA	antibodies	on	long-term	graft	survival	according	
to	 donor	 status	 (3276	 deceased-donor	 and	 1494	 living-donor	
transplantations).	 After	 deceased-donor	 transplantation,	 the	
AKME	according	to	the	presence	of	ARHGDIB	antibodies	showed	
a	10-year	death-censored	graft	survival	of	61%	(95%	CI	50%-70%)	
for	 the	94	of	3276	patients	with	and	73%	 (95%	CI	71%-75%)	 for	
the	3182/3276	patients	without	ARHGDIB	antibodies	(Figure	2A;	
P	=	.017).	Pretransplant	DSA	against	HLA-A/B/DR/DQ	was	found	
in	only	10	of	94	patients	 (10.6%)	with	ARHGDIB	antibodies	 and	
423/3182	patients	(13.3%)	without	(P	=	.454).	A	Kaplan-Meier	anal-
ysis	in	this	small	subgroup	did	not	show	an	indication	for	a	syner-
gistic	effect	of	DSA	and	anti-ARHGDIB	antibodies.	In	addition,	we	
could	find	no	 indication	for	 interaction	between	the	presence	of	
all	studied	autoantibodies,	or	an	effect	of	their	combined	presence	
on	graft	survival.	There	were	no	significant	differences	between	
the	 patient,	 donor,	 and	 transplant	 characteristics	 between	 the	
anti-ARHGDIB	positive	 and	negative	groups	 transplanted	with	 a	
deceased-donor	kidney,	except	the	cold	ischemia	time	was	slightly	
longer	in	anti-ARHGDIB-positive	patients	(23.5	±	7.7	hours)	com-
pared	to	anti-ARHGDIB-negative	patients	(21.8	±	7.2)	transplanted	
with	a	deceased	donor	(P	=	.043,	Table	2).	The	multivariable	analy-
sis,	adjusted	for	the	same	covariates,	showed	that	the	presence	of	
ARHGDIB	antibodies	was	associated	with	a	higher	risk	of	10-year	
graft	 failure	 after	 transplantation	with	 a	 deceased-donor	 kidney	
(Table	1,	HR	1.82,	95%	CI	1.32-2.53,	P	=	 .0003).	At	1	year	after	
transplantation,	 the	HR	was	1.620	 (95%	CI,	0.993-2.643)	 for	 the	
anti-ARHGDIB-positive	 group	 compared	 to	 the	 anti-ARHGDIB-
negative	group	(Table	S3).	Furthermore,	the	rejection-free	survival	
was	comparable	for	patients	with	and	without	antibodies	against	
ARHGDIB	 (Figure	S3).	 For	 the	 living-donor	 transplantations,	 the	
presence	 of	 ARHGDIB	 antibodies	 was	 not	 associated	 with	 de-
creased	 graft	 survival	 (Figure	 2B)	 or	 increased	 risk	 of	 graft	 fail-
ure	in	multivariable	analysis	(Table	1,	HR	1.25,	95%	CI	0.59-2.66,	
P	=	.56).	Finally,	we	also	assessed	the	association	between	type	of	
donor,	anti-ARHGDIB	antibodies,	and	10-year	graft	survival	in	the	
same	model.	The	hazard	 ratio	 for	a	 living	donor	was	0.563	 (95%	
CI	 0.488-0.650,	P	 <	 .0001)	 compared	 to	 deceased	 donors,	 sug-
gesting	that	that	anti-ARHGDIB	was	significantly	associated	with	
graft	loss	in	recipients	transplanted	with	a	kidney	from	a	deceased	
donor	but	not	in	recipients	of	a	living-donor	kidney.
3.3 | ARHGDIB expression in the kidney
Finally,	 we	were	wondering	where	 in	 the	 kidney	 ARHGDIB	 is	 ex-
pressed.	 Therefore,	 we	 stained	 biopsies	 of	 a	 transplanted	 kidney	
without	 histological	 abnormalities	 and	 a	 transplanted	 kidney	with	
acute	tubular	necrosis	using	an	anti-ARHGDIB	antibody.	In	a	trans-
planted	kidney	without	histological	abnormalities,	weak	ARHGDIB	
expression	was	seen	in	endothelial	cells	of	interlobular	arteries,	en-
dothelial	cells	of	peritubular	capillaries,	and	endothelial	cells	of	glo-
merular	capillaries	(Figure	3A).	 In	a	transplanted	kidney	with	acute	
tubular	necrosis,	strong	ARHGDIB	expression	was	seen	in	endothe-
lial	cells	of	interlobular	arteries,	endothelial	cells	of	peritubular	cap-
illaries,	 and	 endothelial	 cells	 of	 glomerular	 capillaries.	 In	 addition,	
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F I G U R E  1   Impact	of	cut-off	for	the	
presence	of	non-HLA	antibodies	against	
ARHGDIB	on	graft	survival.	A,	In	this	
figure	the	hypothesis	is	displayed	that	
the	presence	of	a	non-HLA	antibody	
is	associated	with	graft	failure.	B,	
Using	acquired	data	from	non-HLA	
measurements,	we	determined	the	
difference	in	graft	survival	between	the	
non-HLA	antibody	negative	and	positive	
group	for	various	cut-off	values	at	1,	5,	
and	10	years	after	transplantation	in	a	
univariate	Kaplan-Meier	analysis.	Here,	
the	results	for	directly	coupled	ARHGDIB	
are	used	as	an	example.	The	highest	
difference	in	graft	survival	between	the	
ARHGDIB-positive	and	-negative	group	
was	achieved	with	a	cut-off	for	signal-to-
background	ratio	of	10	in	combination	
with	a	cut-off	for	absolute	MFI	of	500.	
The	graft	survival	difference	for	this	
cut-off	between	the	ARHGDIB-positive	
and	-negative	group	was	5.9%,	10.9%,	
and	13.1%	at	1,	5,	and	10	years	after	
transplantation,	respectively.	C,	Shown	
are	the	percentages	of	ARHGDIB-positive	
patients	for	each	cut-off.	For	the	selected	
cut-off	there	are	2.8%	(134	of	4770)	
positive patients
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positive	staining	for	ARHGDIB	is	also	seen	in	some	podocytes	and	
lymphocytes	(Figure	3B).
4  | DISCUSSION
In	the	present	study,	we	determined	the	relation	between	graft	fail-
ure	 and	 the	 presence	 of	 pretransplant	 non-HLA	 antibodies	 in	 the	
sera	of	4770	kidney	transplantations	performed	in	The	Netherlands	
between	1995	and	2006.	The	results	indicate	that	pretransplant	an-
tibodies	 against	ARHGDIB	 represent	 a	 risk	 factor	 for	 graft	 loss	 in	
deceased-donor	transplantations.
The	 14	 non-HLA	 target	 proteins	 included	 in	 our	 assay	 were	
selected	based	on	 reported	antibody	 specificity	 in	kidney	 trans-
plant	patients	or	patients	with	end-stage	renal	disease,	and	their	
expression	 in	 the	 kidney.	 A	 number	 of	 these	 non-HLA	 antibod-
ies	 have	 been	 examined	 in	 relation	 to	 kidney	 transplantation.	
Antibodies	against	AT1R	were	associated	with	rejection	and	graft	
survival	 according	 to	 results	 from	several	 large-scale	 studies,5,20 
although	a	recent	large	study	(n	=	940)	did	not	confirm	this	asso-
ciation.4	Pretransplant	anti-ETAR	antibodies	have	been	associated	
with	higher	serum	creatinine	values	at	1	year	posttransplantation	
and	 with	 more	 severe	 vascular	 rejection.21	 Antibodies	 against	
LG3,	 a	 C-terminal	 fragment	 of	 perlecan,	 were	 associated	 with	
acute	tubulointerstitial	rejection	and	long-term	renal	allograft	dys-
function.15,22	 Antibodies	 against	 PLA2R,	 LPLUNC,	 APMAP,	 and	
PRKCZ	were	 described	 previously	 in	 small	 case-series	 and	 have	
not	 been	 further	 evaluated.23-25	During	 the	 development	 of	 our	
non-HLA	antibody	assay	we	found	that	MFI	results	on	a	specific	
bead	was	comparable	between	singleplex	and	multiplex	measure-
ment,	indicating	no	occurrence	of	compromise	by	multiplex	anal-
ysis.	 In	general,	non-HLA	antibodies	 frequently	occur	within	 the	
healthy	population	and	 for	many	autoantibodies	a	 serum	 is	 con-
sidered	positive	when	exceeding	a	cut-off	yielding	a	limited	(<5%)	
frequency	of	positive	 results	within	 the	healthy	population.	This	
definition	does	not	necessarily	provide	the	most	clinically	relevant	
cut-off	 value	with	 regard	 to	prognosis.	To	 this	end,	we	chose	 to	
define	a	clinically	 relevant	cut-off	as	 it	was	previously	described	
for	HLA	antibodies	using	a	 combination	of	STBR	combined	with	
a	minimal	MFI	level.26	Using	individual	cut-offs	for	each	non-HLA	
antibody,	 optimally	 discriminating	 patients	 with	 long-term	 func-
tioning	grafts	vs	graft	loss,	we	did	not	find	associations	between	
the	 presence	 of	 any	 of	 the	 abovementioned	 previously	 studied	
non-HLA	antibodies	and	graft	loss,	function,	or	rejection.	We	did	
not	analyze	the	autoantibody	MFI	levels	as	continuous	variables,	
because	in	the	field	of	anti-HLA	antibodies	it	is	well	accepted	that	
MFI	is	not	an	indication	of	antibody	titer	and	is	influenced	by	sev-
eral	factors	such	as	(1)	the	antigen	density,	(2)	the	affinity	of	the	
antibody	to	the	antigen,	and	(3)	the	amount/titer	of	the	antibody	
(also	dependent	on	the	serum	dilution	used	in	the	assay).
At	present,	no	studies	have	been	reported	showing	the	associ-
ation	 between	 anti-ARHGDIB	 antibodies	 and	 graft	 loss.	Here,	we	
found	significant	associations	between	graft	loss	and	the	pretrans-
plant	presence	of	antibodies	against	ARHGDIB.	The	effect	of	these	
antibodies	is	observed	predominantly	in	patients	transplanted	with	
a	deceased-donor	kidney.	This	suggests	an	interaction	between	the	
presence	 of	 anti-ARHGDIB	 antibodies	 and	 ischemia	 reperfusion	
injury,	which	 is	 less	 prominent	 in	 living-donor	 kidney	 transplanta-
tion.27	ARHGDIB	 is	widely	expressed,	 including	 in	 the	 renal	pelvis	
and	glomeruli.	Increased	expression	of	ARHGDIB	has	been	reported	
in	several	 solid	 tumors	and	hematological	malignancies.28-31	Bilalic	
et al32	 first	 described	 that	 dialysis	 patients	 can	 have	 autoreactive	
antibodies	 against	 ARHGDIB.	 Further	 analysis	 in	 kidney	 biopsies	
showed	 cytoplasmic	 expression	 in	 endothelial	 cells	 of	 interlobular	
F I G U R E  2  Graft	survival	according	to	the	presence	of	pretransplant	non-HLA	antibodies	in	deceased	donor	and	living-donor	kidney	
transplantation.	Inverse	probability	weighting	(IPW)	adjusted	Kaplan-Meier	estimate	(AKME)	for	death-censored	graft	survival	according	to	
the	presence	of	ARHGDIB	in	3276	deceased	(A)	and	1494	living-donor	(B)	transplantations.	AKME	was	adjusted	for	the	following	covariates:	
recipient	age	(quadratic)	and	donor	age	(quadratic),	cold	ischemia	time	(for	donation	after	brain	death	and	donation	after	cardiac	death),	
time	on	dialysis	in	years	(quadratic),	induction	therapy	with	IL-2	receptor	blocker,	and	the	presence	of	pretransplant	donor-specific	anti-HLA	
antibodies	(DSA)
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Characteristics
ARHGDIB 
negative 
(N = 3182)
ARHGDIB pos‐
itive (N = 94) P‐value
Deceased‐donor 
transplantations 
(N = 3276)
Patient
Age	at	transplantation	
(y,	mean	±	SD)
46.9	±	14.1 47.9	±	13.4 .462a 46.1	±	14.1
Female	sex	-	no.	(%) 1286	(40.4) 39	(41.5) .834b 1325	(40.5)
PRA	at	time	of	
transplantation	(%,	
mean	±	SD)
6.8	±	18.7 9.2	±	25.1 .574a 6.9	±	18.9
Highest	PRA	(%,	
mean	±	SD)
16.4	±	28.2 15.4	±	30.4 .300a 16.4	±	28.2
Dialysis,	n	(%)   .455b  
No 147	(4.6) 3	(3.0)  150	(4.6)
Yes	–	hemodialysis 1853	(58.2) 49	(52.1)  1902	(58.1)
Yes – peritoneal 
dialysis
1164	(36.6) 41	(43.6)  1205	(36.8)
Unknown 18	(0.6) 1	(1.1)  19	(0.6)
Time	on	dialysis	(y,	
mean	±	SD)
3.4	±	2.6 3.4	±	2.2 .814a 3.4	±	2.6
Donor     
Donor	age	(y,	
mean	±	SD)
42.7	±	16.0 46.0	±	14.6 .062a 42.8	±	16.0
Donor	female	sex	–	
no.	(%)
1489	(46.8) 46	(48.9) .681b 1535	(46.9)
Cold-ischemia	time	
(hours,	mean	±	SD)
21.8	±	7.2 23.5	±	7.7 .043a 21.8	±	7.2
Transplant     
Repeat transplantation 
–	no.	(%)
554	(17.4) 16	(17.0) .922b 570	(17.4)
Pretransplant	DSA	
against	HLA-A/B/DR/
DQ	–	no.	(%)	
423	(13.3) 10	(10.6) .454b 433	(13.2)
Induction	therapy     
IL-2	receptor	blocker	
–	no.	(%)	
651	(20.5) 14	(14.9) .186b 665	(20.3)
T-cell	depleting	
antibodyc	no.	(%)
134	(4.2) 0	(0) .042b 134	(4.1)
Initial	immunosuppres-
sion	–	no.	(%)
    
Steroids 3120	(98.1) 90	(95.7) .117b 3210	(98.0)
MMF/azathioprine 2377	(74.7) 63	(67.0) .092b 244	(74.4)
Cyclosporine/
tacrolimus
3000	(94.3) 88	(93.6) .785b 3088	(94.3)
Sirolimus 171	(5.4) 9	(9.6) .078b 180	(5.4)
Other 417	(13.1) 11	(11.7) .691b 428	(13.1)
Unknown 11	(0.4) 1	(1.1) .256b 12	(0.4)
DSA,	Donor-specific	anti-HLA	antibodies;	IL,	interleukin;	MMF,	mycophenolate	mofetil.
aMann-Whitney	U	test	for	continuous	variables.	
bChi-square	test	for	categorical	variables.	
cT	cell-depleting	antibody	therapy:	ALG,	ATG,	OKT3	monoclonal	antibodies.	
TA B L E  2  Characteristics	of	ARHGDIB-
positive	and	ARHGDIB-negative	patients	
transplanted	with	a	deceased-donor	
kidney
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arteries	and	peritubular	capillaries,	and	 in	podocytes.	We	consider	
it	possible	that	cellular	damage	caused	by	ischemia	reperfusion	re-
sults	 in	accessibility	of	ARHGDIB	 in	endothelial	cells	 to	circulating	
auto-antibodies.	After	binding,	anti-ARHGDIB	antibodies	may	initi-
ate	 complement	 activation	 causing	 local	 inflammation,	which	may	
explain	why	 a	 relation	between	 their	 presence	 and	 graft	 loss	was	
observed	only	after	deceased-donor	transplantation.
In	our	study,	non-HLA	proteins	were	coated	directly	or	indirectly	
(via	HaloTag)	to	the	microspheres.	This	strategy	was	chosen	because	
the	coupling	process	may	influence	the	conformation	and	accessibility	
of	epitopes	predominantly	recognized	on	non-HLA	beads.11	Previously	
we	found	that	the	correlation	between	results	obtained	with	our	test	
and	with	commercial	assays	depended	on	the	coupling	method	of	the	
proteins.	This	demonstrates	 the	necessity	of	complete	 transparency	
and	detailed	description	of	methods	when	comparing	 the	effects	of	
non-HLA	 antibodies	 in	 patient	 groups.	 Because	 there	 are	 no	 com-
mercially	available	reference	sera	against	the	non-HLA	antibodies	we	
selected,	we	were	not	 able	 to	properly	 compare	our	 Luminex	assay	
to	 other	 commercially	 available	 ELISA	 or	 Luminex	 autoantibody	 as-
says.	In	the	sera	used	in	our	multiplex	assay,	we	measured	non-HLA	
IgG	antibodies.	 It	 is	possible	that	some	non-HLA	antibodies	relevant	
to	prognosis	 are	of	 another	 isotype	and	were	not	detected	here.	 In	
some	autoimmune	diseases,	autoantibodies	are	of	other	isotypes,	such	
as	IgM-RF	or	IgA-anti-tTG.	However,	most	clinically	relevant	autoanti-
bodies	are	of	the	IgG	isotype.	We	also	examined	whether	a	reactivity	
pattern	 between	 non-HLA	 antibodies	 can	 be	 distinguished,	 for	 in-
stance	due	to	cross-reactivity,	but	we	did	not	find	significant	associ-
ations	between	each	of	the	14	non-HLA	antibodies	investigated	and	
there	was	no	relationship	with	pretransplant	DSA.
In	a	large	cohort	studied	by	Opelz,	a	9%	difference	in	10-year	graft	
survival	was	observed	between	recipients	of	HLA-identical	sibling	do-
nors	with	or	without	panel-reactive	HLA	antibodies,	which	led	to	the	
conclusion	that	a	high	immunization	grade	against	HLA	may	indicate	
an	increased	immunity	against	non-HLA.33	In	our	study,	the	observed	
adverse	effects	of	non-HLA	antibodies	were	independent	of	the	pres-
ence	of	DSA	as	we	adjusted	for	this	covariable.	Because	ARHGDIB	is	
considered	to	be	a	minor	histocompatibility	antigen,	we	examined	the	
relation	between	antibody	levels	and	potentially	immunizing	events,	
but	found	no	link	with	repeat	transplantation,	female	sex,	pregnancies,	
or	potentially	confounding	factors	such	as	diabetes	type	1,	or	several	
primary	renal	diseases.	Therefore,	mechanisms	may	be	involved	in	the	
induction	of	non-HLA	antibody	formation	other	than	the	well-known	
sensitizing	events	stimulating	HLA	antibody	production.
We	were	not	able	to	include	posttransplant	samples	(sera	and/or	bi-
opsies)	in	our	study,	thereby	limiting	the	use	of	results	in	pretransplant	
risk	 stratification.	 Future	 studies	 have	 to	 be	 performed	 to	 evaluate	
whether	posttransplant	monitoring	of	anti-ARHGDIB	is	useful.	Another	
limitation	of	the	study	was	that	we	did	not	have	detailed	clinical	infor-
mation,	such	as	autoimmune	diseases	or	hypertension,	 to	potentially	
link	the	presence	of	anti-ARHGDIB	antibodies	to	a	clinical	parameter.	
Due	to	lack	of	detailed	rejection	and	histology	information,	we	cannot	
directly	link	anti-ARHGDIB	antibodies	with	the	rejection	phenotype.
In	 conclusion,	 our	 study	 demonstrates	 that	 pretransplant	 non-
HLA	antibodies	against	ARHGDIB	are	a	significant	risk	factor	in	de-
ceased-donor	transplantation.	These	antibodies	occur	independently	
from	DSA	or	other	non-HLA	antibodies	 investigated.	 It	 is	 currently	
unknown	whether	 the	presence	of	 these	antibodies	 is	a	biomarker,	
as	 is	 the	 case	 in	many	 autoimmune	diseases,	 or	whether	 they	play	
a	 role	 in	 the	 pathogenesis	 of	 graft	 loss.	Although	 validation	 of	 our	
findings	in	independent	cohorts	is	necessary,	based	on	these	results,	
we	 suggest	 that	 pretransplant	 risk	 assessment	 can	be	 improved	by	
measuring	 these	antibodies	 in	all	patients	awaiting	deceased-donor	
transplantation.
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